REG - Alliance Pharma PLC - Director Dealings

Alliance PharmaAnnouncement

16/10/2023 18:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231016:nRSP2931Qa&default-theme=true

RNS Number : 2931Q  Alliance Pharma PLC  16 October 2023

 

   16 October 2023

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Director Dealings

 

Alliance Pharma plc (AIM: APH), the international healthcare group, has been
notified that on 13(th) October 2023 each of Peter Butterfield, Chief
Executive Officer of Alliance, and Andrew Franklin, Chief Financial Officer,
have exercised share options pursuant to the Company's Long Term Incentive
Plan as set out below.

 

Peter Butterfield has exercised options over 98,342 ordinary shares of 1 pence
each in the Company ("Ordinary Shares"). These options were granted in 2019 at
nil cost and were set to expire on 5 December 2023. Following this exercise,
74,343 Ordinary Shares were sold at a price of £0.39016 per share, with an
element of the proceeds being applied to satisfy the nominal value exercise
price of the options, costs and tax liabilities. In accordance with the
Company's share retention policy, following this transaction, Mr Butterfield
has a beneficial interest in 466,103 Ordinary Shares and 1,818,750 vested but
unexercised share options.

 

Andrew Franklin has exercised options over 55,592 Ordinary Shares. These
options were granted in 2019 at nil cost and were set to expire on 5 December
2023. Following this exercise, 42,053 Ordinary Shares were sold at a price of
£0.39016 per share, with an element of the proceeds being applied to satisfy
the nominal value exercise price of the options, costs and tax liabilities. In
accordance with the Company's share retention policy, following this
transaction, Mr Franklin has a beneficial interest in 192,911 Ordinary Shares
and 1,450,501 vested but unexercised share options.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Peter Butterfield
 2   Reason for the notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification /Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         ALLIANCE PHARMA PLC
 b)  Legal Entity Identifier                                      213800RYIWZA4Q5WPZ13
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 1 pence each

     Identification code

                                                                  GB0031030819
 b)  Nature of the transaction                                    a)   Exercise of options

                                                                  b)   Sale of Ordinary Shares
 c)  Currency                                                     GBP
 d)  Price(s) and volume(s)                                       Price(s)                                  Volume(s)
     a)   1 pence (nominal value)                                                                           a) 98,342

     b)   £0.39016                                                                                          b) 74,343

 e)  Aggregated information                                       a) 98,342 options over Ordinary Shares, at nil cost save par value per share

                                                            (being 1 pence per share and an aggregate of £983.42).
     - Aggregated volume

     - Price

                                                            b) 74,343 Ordinary Shares, sold at an average price of £0.39016 per Ordinary
     - Aggregated total                                           Share, totalling £29,005.66

 f)  Date of the transaction(s)                                   13 October 2023
 g)  Place of the transaction                                     London Stock Exchange, AIM

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Andrew Franklin
 2   Reason for the notification
 a)  Position/status                                              Chief Financial Officer
 b)  Initial notification /Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         ALLIANCE PHARMA PLC
 b)  Legal Entity Identifier                                      213800RYIWZA4Q5WPZ13
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 1 pence each

     Identification code

                                                                  GB0031030819
 b)  Nature of the transaction                                    c)    Exercise of options

                                                                  d)   Sale of Ordinary Shares
 c)  Currency                                                     GBP
 d)  Price(s) and volume(s)                                       Price(s)                                 Volume(s)
     c)    1 pence (nominal value)                                                                         a) 55,592

     d)   £0.39016                                                                                         b) 42,053

 e)  Aggregated information                                       a) 55,592 options over Ordinary Shares, at nil cost save par value per share

                                                            (being 1 pence per share and an aggregate of £555.92)
     - Aggregated volume

     - Price

                                                            b) 42,053 Ordinary Shares, sold at an average price of £0.39016  pence per
     - Aggregated total                                           Ordinary Share, totalling £16,407.40

 f)  Date of the transaction(s)                                   13 October 2023
 g)  Place of the transaction                                     London Stock Exchange, AIM

 

 

For further information:

 

 Alliance Pharma plc                                                     + 44 (0)1249 466966
 Head of Investor Relations: Cora McCallum                               + 44 (0)1249 705168
 ir@allianceph.com (mailto:ir@allianceph.com)

 Buchanan                                                                + 44 (0)20 7466 5000
 Mark Court / Sophie Wills / Hannah Ratcliff
 alliancepharma@buchanan.uk.com (mailto:alliancepharma@buchanan.uk.com)

 Numis Securities Limited (Nominated Adviser and Joint Broker)           + 44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Sher Shah

 Investec Bank plc (Joint Broker)                                        + 44 (0)20 7597 5970
 Patrick Robb / Maria Gomez de Olea

 

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our
purpose is to empower people to make a positive difference to their health and
wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and
channels, in related innovation, and through selective geographic expansion to
increase the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics we remain asset-light and focused
on maximising the value we can bring, both to our stakeholders and to our
brands. For more information on Alliance, please visit our
website: www.alliancepharmaceuticals.com
(http://www.alliancepharmaceuticals.com/)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHMZMMGNVGGFZM